Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Cardiovascular & Metabolic 

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide representing almost a third of all deaths globally1. The rates of CVD-related morbidity are on the rise as many countries face ageing populations and increasing rates of obesity. Pfizer aims to tackle this worldwide problem with our products that cover both the prevention and treatment of life-threating cardiovascular events.

Other products within our portfolio include

ACCUPRO™

(quinapril hydrochloride)

Summary of Product Characteristics

ACCURETIC™

(quinapril 10mg, hydroclorothiazide 12.5mg)

Summary of Product Characteristics

ALDACTIDE®

(hydroflumethiazide, spironolactone)

Summary of Product Characteristics

ALDACTONE®

(spironolactone)

Summary of Product Characteristics

COLESTID®

(colestipol hydrochloride)

Summary of Product Characteristics

CYKLOKAPRON®

(tranexamic acid)

Summary of Product Characteristics

DOPAMINE

(dopamine hydrochloride)

Summary of Product Characteristics

GLYCERYL TRINITRATE

(glyceryl trinitrate)

Summary of Product Characteristics

HYPOVASE™

(prazosin hydrochloride)

Summary of Product Characteristics

NORADRENALINE

(noradrenaline tartrate)

Summary of Product Characteristics

OCTREOTIDE

(octreotide acetate)

Summary of Product Characteristics

PROSTIN VR®

(alprostadil)

Summary of Product Characteristics
Back to top